Evidence map›Paper›PMID 38140081›Full record

ArticlePharmaceutics2023

Carrier-Tumor Cell Membrane Interactions for Optimized Delivery of a Promising Drug, 4(

Ariana Abawi, Céline Thomann, Giovanna Lollo, Thierry Granjon, Emma Petiot, Anna Bérot, Camille Oger, Valérie Bultel-Poncé, Alexandre Guy, Jean-Marie Galano and 3 more

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Membrane-Inserting α‑Lipid Polymers: Understanding Lipid Membrane Insertion and Effect on Membrane Fluidity.Chemistry of materials : a publication of the American Chemical Society · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Ariana AbawiInstitute of Molecular and Supramolecular Chemistry and Biochemistry, ICBMS UMR 5246, University Lyon, Université Lyon 1, CNRS, F-69622 Lyon, France.
Céline ThomannInstitute of Molecular and Supramolecular Chemistry and Biochemistry, ICBMS UMR 5246, University Lyon, Université Lyon 1, CNRS, F-69622 Lyon, France.
Giovanna LolloLaboratoire d'Automatique, de Génie des Procédés et de Génie Pharmaceutique, LAGEPP UMR 5007, University Lyon, Université Lyon 1, CNRS, F-69622 Lyon, France.ORCID 0000-0001-7030-3056
Thierry GranjonInstitute of Molecular and Supramolecular Chemistry and Biochemistry, ICBMS UMR 5246, University Lyon, Université Lyon 1, CNRS, F-69622 Lyon, France.
Emma PetiotInstitute of Molecular and Supramolecular Chemistry and Biochemistry, ICBMS UMR 5246, University Lyon, Université Lyon 1, CNRS, F-69622 Lyon, France.
Anna BérotInstitute of Molecular and Supramolecular Chemistry and Biochemistry, ICBMS UMR 5246, University Lyon, Université Lyon 1, CNRS, F-69622 Lyon, France.
Camille OgerPôle Chimie Balard Recherche, Institut des Biomolécules Max Mousseron, IBMM, UMR 5247, Université de Montpellier, CNRS, ENSCM, F-34293 Montpellier, France.ORCID 0000-0002-5177-5792
Valérie Bultel-PoncéPôle Chimie Balard Recherche, Institut des Biomolécules Max Mousseron, IBMM, UMR 5247, Université de Montpellier, CNRS, ENSCM, F-34293 Montpellier, France.
Alexandre GuyPôle Chimie Balard Recherche, Institut des Biomolécules Max Mousseron, IBMM, UMR 5247, Université de Montpellier, CNRS, ENSCM, F-34293 Montpellier, France.
Jean-Marie GalanoPôle Chimie Balard Recherche, Institut des Biomolécules Max Mousseron, IBMM, UMR 5247, Université de Montpellier, CNRS, ENSCM, F-34293 Montpellier, France.
Thierry DurandPôle Chimie Balard Recherche, Institut des Biomolécules Max Mousseron, IBMM, UMR 5247, Université de Montpellier, CNRS, ENSCM, F-34293 Montpellier, France.ORCID 0000-0001-6086-7296
Agnès Girard-EgrotInstitute of Molecular and Supramolecular Chemistry and Biochemistry, ICBMS UMR 5246, University Lyon, Université Lyon 1, CNRS, F-69622 Lyon, France.ORCID 0000-0003-2612-3124
Ofelia ManitiInstitute of Molecular and Supramolecular Chemistry and Biochemistry, ICBMS UMR 5246, University Lyon, Université Lyon 1, CNRS, F-69622 Lyon, France.ORCID 0000-0001-9371-9580
Université Claude Bernard Lyon 1 · FRÉcole Nationale Supérieure de Chimie de Montpellier · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanomedicines engineered to deliver molecules with therapeutic potentials, overcoming drawbacks such as poor solubility, toxicity or a short half-life, are targeted towards their cellular destination either passively or through various elements of cell membranes. The differences in the physicochemical properties of the cell membrane between tumor and nontumor cells have been reported, but they are not systematically used for drug delivery purposes. Thus, in this study, a new approach based on a match between the liposome compositions, i.e., membrane fluidity, to selectively interact with the targeted cell membrane was used. Lipid-based carriers of two different fluidities were designed and used to deliver 4(

Indexed as

4(RS)-4-F4t-Neuroprostanedrug deliveryliposomesmembrane fluidity

Identifiers

PMID38140081
PMCPMC10748318
OpenAlexW4389443556

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.